Exchange: NASDAQ·Updated 07:59 PM EST

MRKR News

News
all
press releases
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers VivoSim Labs (NASDAQ:VIVS) shares increased by 82.0% to $0.22 during Thursday's regular session. The market value of their outstanding shares is at $2.4 million. Marker Therapeutics (NASDAQ:MRKR) sharesread more...
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Gainers VivoSim Labs (NASDAQ:VIVS) shares increased by 82.0% to $0.22 during Thursday's regular session. The market value of their outstanding shares is at $2.4 million. Marker Therapeutics (NASDAQ:MRKR) sharesread more...
Benzinga
More News
MARKER THERAPEUTICS (MRKR) delivered earnings and revenue surprises of +16.67% and -47.23%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Rigel (RIGL) delivered earnings and revenue surprises of -25.29% and +3.35%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
MARKER THERAPEUTICS (MRKR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks
UGP, SCSC, MRKR, SLGL and MEOH have been added to the Zacks Rank #1 (Strong Buy) List on October 16, 2026.
Zacks
Aurinia (AUPH) delivered earnings and revenue surprises of +47.37% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Indivior, Aurinia, Ironwood, Altimmune and Marker have been highlighted in this Industry Outlook article.
Zacks
Innovation is at its peak in the Zacks Medical-Drugs industry. INDV, AUPH, IRWD, ALT and MRKR may prove to be good additions to one's portfolio.
Zacks
MARKER THERAPEUTICS (MRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Zacks
PROKIDNEY CP (PROK) delivered earnings and revenue surprises of -7.69% and +222.86%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks

Advertisement|Remove ads.